INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
7.88
+0.09 (+1.16%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.79
Open7.79
Bid6.00 x 200
Ask8.19 x 100
Day's Range7.70 - 8.03
52 Week Range4.10 - 15.02
Volume267,394
Avg. Volume1,645,798
Market Cap577.735M
Beta2.19
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateMar 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.80
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    INSYS Therapeutics to Report Fourth Quarter 2017 Results on March 8

    PHOENIX, Feb. 23, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release ...

  • Benzinga5 days ago

    Wonder Women Of Weed: Jodie Emery, The Entrepreneurial Rebel With A Cause

    " Wonder Women Of Weed " is a bi-monthly show and column featuring accomplished female leaders in the cannabis industry, brought from a collaborative effort that includes Benzinga, Industry Power ...

  • GlobeNewswire5 days ago

    INSYS Therapeutics to Present at RBC Healthcare Conference

    PHOENIX, Feb. 20, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...

  • TheStreet.com11 days ago

    Opioid Litigants Get Boost From Senate Report

    A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

  • Reuters12 days ago

    Opioid makers paid millions to advocacy groups -U.S. Senate report

    Five opioid manufacturers including OxyContin maker Purdue Pharma LP have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday. The report, released by Democratic Senator Claire McCaskill, said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42,000 opioid overdose deaths. The report released by McCaskill, the U.S. Senate Homeland Security and Governmental Affairs Committee's ranking Democrat, said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use.

  • Stocks give up early gains, Trump signs budget bill
    Yahoo Finance16 days ago

    Stocks give up early gains, Trump signs budget bill

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • GlobeNewswire16 days ago

    INSYS Therapeutics Addresses Maryland Attorney General’s Motion

    PHOENIX, Feb. 09, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement ...

  • Reuters16 days ago

    Maryland sues Insys to enforce subpoena in opioid probe

    Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine. Maryland Attorney General Brian Frosh confirmed on Thursday that his office filed a lawsuit in state court after Insys resisted turning over documents sought as part of an investigation into the drugmaker's role in the opioid epidemic. Frosh said the state had been investigating the Chandler, Arizona-based company since 2016 amid allegations that Insys had marketed its product Subsys to not just patients with severe cancer pain but for other conditions.

  • American City Business Journals19 days ago

    See which Valley public companies were among U.S. stocks that suffered the most last week

    The U.S. stock markets had their worst week in months last week, ending with the biggest loss since President Donald Trump took office on Friday. The plunge came after U.S. jobs figures were announced ...

  • Look Beyond Pharma to Invest in Marijuana Industry
    Insider Monkey23 days ago

    Look Beyond Pharma to Invest in Marijuana Industry

    In this article we are going to present an alternative to weed stocks such as GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Cara Therapeutics Inc (NASDAQ:CARA), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), and Insys Therapeutics Inc (NASDAQ:INSY). When it comes to investing in the marijuana industry many people think about stocks of companies that are either growing and/or selling […]

  • Reuters23 days ago

    New York accuses Insys of deceptively marketing opioid

    Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses. New York Attorney General Eric Schneiderman alleged that the Chandler, Arizona-based drugmaker recklessly marketed its product Subsys for wider uses than the U.S. Food and Drug Administration approved and bribed doctors to prescribe it. "At a time when the opioid epidemic was ravaging New York, Insys Therapeutics allegedly marketed a drug illegally by blatantly disregarding the grave risks of addiction and death that opioids pose," Schneiderman said in a statement.

  • GlobeNewswire23 days ago

    INSYS Therapeutics Addresses New York Attorney General’s Complaint

    PHOENIX, Feb. 01, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement ...

  • Investopedia23 days ago

    Top 4 Marijuana Stocks to Watch

    These four stocks are top picks that capitalize on the marijuana industry.

  • GlobeNewswire24 days ago

    INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors

    PHOENIX, Feb. 01, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of ...

  • GlobeNewswire26 days ago

    INSYS Therapeutics Adds Two New Executives to Senior Management Team

    VP of Human Resources, Carol Summersgill; VP of Clinical Development, Dr. PHOENIX, Jan. 30, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical ...

  • Why Marijuana and Cryptocurrency Investments Differ
    Market Realist27 days ago

    Why Marijuana and Cryptocurrency Investments Differ

    In the earlier part of this series, we briefly discussed why investors have recently rushed into cryptocurrencies and marijuana. In this part, we’ll discuss the difference between these investment opportunities, starting with the marijuana industry (MJX). Businesses exist to provide value to an end user, and marijuana’s end use has been fairly well-established. There has been an established market for medical marijuana in several countries.

  • Benzingalast month

    Cannabis Industry Group Announces National Standards, Starts With Marijuana Product Packaging And Labeling

    One of the consequences of cannabis remaining federally illegal is the lack of unified standards for operating businesses. Every state, municipality and jurisdiction compels marijuana businesses to fulfill ...

  • What Vermont Can Learn from Washington’s Marijuana Tax
    Market Realistlast month

    What Vermont Can Learn from Washington’s Marijuana Tax

    In the previous article in this series, we saw that Vermont decriminalized recreational marijuana on January 22, 2018. With no legality covering the sale of marijuana and no tax revenues from these sales, what would motivate Vermont to legalize recreational marijuana?

  • Vermont Legalizes Recreational Marijuana on January 22, 2018
    Market Realistlast month

    Vermont Legalizes Recreational Marijuana on January 22, 2018

    On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.

  • The Other Side of Legalizing Recreational Marijuana
    Market Realistlast month

    The Other Side of Legalizing Recreational Marijuana

    While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.

  • What a Country Could Gain from Legalizing Recreational Marijuana
    Market Realistlast month

    What a Country Could Gain from Legalizing Recreational Marijuana

    In the previous part of this series, we saw how the legalization of recreational marijuana could create related business opportunities. In this part, we’ll discuss the potential upside of recreational marijuana for a country like Canada. According to Deloitte, recreational marijuana alone could be a $5 billion industry initially, and it could go as high as $8.7 billion.

  • The Marijuana Ecosystem’s Potential Business Opportunities
    Market Realistlast month

    The Marijuana Ecosystem’s Potential Business Opportunities

    In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.

  • Is Investment in the Marijuana Space Picking Up?
    Market Realistlast month

    Is Investment in the Marijuana Space Picking Up?

    In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy. With too much confusion surrounding the legalities of the marijuana industry, some seasoned players appear highly optimistic about the future of recreational marijuana. Late last year, Constellation Brands (STZ) agreed to acquire a 9.9% stake in the Canada-based Canopy Growth for about $191.3 million.

  • The Motivation for Recreational Marijuana Consumption
    Market Realistlast month

    The Motivation for Recreational Marijuana Consumption

    In this part, we look at the secondary use of marijuana, recreational use. In mid-2018, Canada is expected to make marijuana legal for recreational use. This outlook has been driving stocks such as Aurora Cannabis (ACB.TO), Canopy Growth (WEED.TO), Aphria (APH.TO), and MedReleaf (LEAF.TO) to new highs.

  • Why the Medical Marijuana Industry Is Growing
    Market Realistlast month

    Why the Medical Marijuana Industry Is Growing

    Must-Knows before Investing in the Marijuana Industry